Navigation Links
WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release
Date:4/30/2009

Earnings Conference Call to be Held on May 15, 2009 at 8:00 am (Eastern) / 5:00 am (Pacific) / 8:00 pm (Beijing/Shanghai/Hong Kong)

SHANGHAI, May 1 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that it will release financial results for the first quarter of 2009 on May 15, 2009 Shanghai time, and after the U.S. market closes on Thursday, May 14, 2009 New York time.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

The earnings release will be available on the investor relations section of its website at http://www.wuxiapptec.com.

Following the earnings announcement, WuXi PharmaTech senior management will host a conference call at 8:00 am (Eastern) / 5:00 am (Pacific) / 8:00 pm (Beijing/Shanghai/Hong Kong) on Friday, May 15, 2009, to discuss its 2009 first-quarter financial results and recent business activities. The conference call may be accessed by calling:

        United States: 1-866-519-4004
        China (Landline): 800-819-0121
        China (Mobile): 400-620-8038
        Hong Kong: 800-933-053
        United Kingdom: 0-808-234-6646
        International: +65-6735-7955
        Conference ID: 96870349
        Web PIN: 8656

A telephone replay will be available two hours after the call's completion at:

        United States: 1-866-214-5335
        China North: 10-800-714-0386
        China South: 10-800-140-0386
        Hong Kong: 800-901-596
        United Kingdom: 0-800-731-7846
        International: +61-2-8235-5000
        P
'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pharmatech Oncology Selected to Present at Company Showcase at BIOZONA
2. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results
3. The Fitzsimons Redevelopment Authority Selects Pharmatech Oncology as Preferred Vendor
4. Quest PharmaTech Announces Strategic Alliance with IntelligentNano to Develop Nanotechnology-Based Next Generation SL052
5. Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors
6. Quest PharmaTech Announces a Review of Strategic Alternatives to Enhance Shareholder Value
7. WuXi PharmaTech to Present at 27th Annual J.P. Morgan Healthcare Conference
8. Pharmatech 2.0: Introducing Pharmatech Oncology
9. WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services
10. WuXi PharmaTech Appoints Ying Han to Its Board of Directors
11. WuXi PharmaTech Announces Third Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA ... disease. One of these latent viruses is the Epstein ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... by the theory, a study found that RA patients ... (1). , What is Microcompetition? , Dr. Hanan ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... of high throughput research solutions, today announced that ... companies, has received delivery of Freeslate’s CM ... form screening. , Lupin, headquartered in Mumbai, ... quality, affordable generic and branded formulations and Active ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, ... Foundation, the only national nonprofit organization solely dedicated to ... quality of life for those affected worldwide, will host ... Warrington Country Club in Warrington, Pa. , Each ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider ... major scientific, regulatory, business, and media events in ... , today announced its former associate Virginia Cox , ... office. Virginia Cox re-joins ... Commissioner for the Office of External Affairs at the U.S. ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
... N.M., Dec. 12 Biomoda, Inc. (OTC,Bulletin Board: ... New,Mexico Institute of Mining and Technology (New Mexico ... to collaborate on clinical,studies and the development of ... commercialization of its assay for the early,detection of ...
... mg/Day Dose for PRISTIQ for the ... Treatment of Major Depressive Disorder, COLLEGEVILLE, Pa., ... WYE ), announces that data from,two Phase 3 clinical studies ... patients who received a 50 mg/day dose of PRISTIQ for ...
... expanding pipeline of products to ... treat ophthalmic diseases, ... developing novel therapeutics for the treatment,of ophthalmic diseases announced today ... a strong, international syndicate of new and,existing investors led by ...
Cached Biology Technology:Biomoda Announces Collaborative Agreement With New Mexico Tech 2New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 2New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 3New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 4New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 5New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 6Fovea Pharmaceuticals Completes EUR30M Series B Financing 2Fovea Pharmaceuticals Completes EUR30M Series B Financing 3Fovea Pharmaceuticals Completes EUR30M Series B Financing 4
(Date:4/15/2014)... global experts who study the deadliest infectious diseases recognized ... Ksiazek, professors at the University of Texas Medical Branch, ... International Symposium on Filoviruses. The filoviruses include Ebola and ... percent of people infected. The current outbreak of Ebola ... 100 deaths so far. , "This award represents ...
(Date:4/15/2014)... Zealand,s pastoral landscapes are some of the loveliest in ... Many of the country,s pasture soils have become enriched ... which is then eaten by the cattle and sheep ... New Zealand; cadmium-enriched soils being reported worldwide. , The ... levels in meat and dairy products, human health and ...
(Date:4/15/2014)... Sciences (KNAW) has announced the names of five internationally ... (one million US dollars prize money in total). The ... to science. , This year marks the 50th anniversary ... chemist Erwin Chargaff in 1964. , KNAW juries ... laureates: , Christopher M. Dobson, John Humphrey ...
Breaking Biology News(10 mins):International research group recognizes UTMB experts 2International research group recognizes UTMB experts 3Five scientists awarded prestigious Heineken Prizes 2
... and Molecular Biology of Universitat Autnoma de Barcelona ... with a tendency to cause conformational diseases such ... amyloidotic cardiomyopathy, etc. finally end up causing them. ... 3D structure and studied why these proteins finally ...
... protein found present in all cells in the body could ... at the University of Edinburgh have found that the protein ... in lipid droplets the parts of cells used to ... of invadolysin were linked to reduced amounts of fat deposits. ...
... was a frightening failure in drug safety processes. In ... died after being administered contaminated doses of the common ... in China and discovered with the help of scientists ... pure heparin that is was undetectable to all but ...
Cached Biology News:Mechanism related to the onset of various genetic diseases revealed 2Mechanism related to the onset of various genetic diseases revealed 3Rensselaer leads effort to replace 1 of the most widely used drugs in American hospitals 2Rensselaer leads effort to replace 1 of the most widely used drugs in American hospitals 3
Large-capacity refrigerated incubator chamber holds up to 4 independently-operated shakers. Programmable heat, refrigeration, humidifcation are standard. Photosynthetic operation, optional....
...
... and disposable ESI Chip allow users to ... electrospray mass spectrometers for life science applications. ... to either speed analysis for increased throughput ... or long acquisition times for proteomics and ...
... are optimised for SYBR Green I assays and ... PCR, with the exception of template and primers. ... levels of active SYBR Green I dye and ... buffer that enables detection of low copy number ...
Biology Products: